Terryanne Standell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Terryanne Standell has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Jamie Leckie
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada
2 shared publications - Sunny Wu
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada
2 shared publications - Toshifumi Yokota
University of Alberta, Edmonton, Canada, CANADA
2 shared publications
Latest Publications
- Open Access
Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders
Rare neuromuscular disorders impose a significant burden on patients, caregivers, and the health care system, yet, effective disease-modifying therapies remain limited. Antisense oligonucleotides (ASOs) have emerged as a promising therapeutic strategy, enabling targeted modulation of gene expression through mechanisms such as exon skipping, exon inclusion, and transcript degradation. However, the clinical efficacy of currently approved ASO therapies is often suboptimal. This limitation reflects not only poor target tissue uptake and delivery barriers, but also suboptimal design of ASO sequences and chemical modification patterns, which can compromise potency, safety, and translational robustness. Recent advances in machine learning have led to the development of ASO optimization platforms such as eSkipFinder and ASOptimizer, which aim to predict effective ASO sequences and chemistries for specific RNA targets. While these tools show considerable promise, their broader applicability remains limited due to a lack of comprehensive validation and the absence of integrated safety considerations. Further refinement and validation are necessary to improve their translational utility. Nevertheless, such platforms represent a critical advancement toward accelerating ASO development. By improving design precision, reducing reliance on extensive preclinical screening, and enabling researchers with limited ASO experience to generate optimized candidates, machine learning is poised to accelerate the development and clinical translation of ASO therapies for rare neuromuscular disorders.
Open AccessArtificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders
Rare neuromuscular disorders impose a significant burden on patients, caregivers, and the health care system, yet, effective disease-modifying therapies remain limited. Antisense oligonucleotides (ASOs) have emerged as a promising therapeutic strategy, enabling targeted modulation of gene expression through mechanisms such as exon skipping, exon inclusion, and transcript degradation. However, the clinical efficacy of currently approved ASO therapies is often suboptimal. This limitation reflects not only poor target tissue uptake and delivery barriers, but also suboptimal design of ASO sequences and chemical modification patterns, which can compromise potency, safety, and translational robustness. Recent advances in machine learning have led to the development of ASO optimization platforms such as eSkipFinder and ASOptimizer, which aim to predict effective ASO sequences and chemistries for specific RNA targets. While these tools show considerable promise, their broader applicability remains limited due to a lack of comprehensive validation and the absence of integrated safety considerations. Further refinement and validation are necessary to improve their translational utility. Nevertheless, such platforms represent a critical advancement toward accelerating ASO development. By improving design precision, reducing reliance on extensive preclinical screening, and enabling researchers with limited ASO experience to generate optimized candidates, machine learning is poised to accelerate the development and clinical translation of ASO therapies for rare neuromuscular disorders.
- Open Access
- 18 September 2025
- Published by MDPI AG in Preprints.org
Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders
Rare neuromuscular disorders impose a significant burden on patients, caregivers, and the health care system. However, effective disease-modifying therapies remain limited. Antisense oligonucleotides (ASOs) have emerged as a promising therapeutic strategy, en-abling targeted modulation of gene expression through mechanisms such as exon skip-ping, exon inclusion, and transcript degradation. Despite the clinical approval of several ASO therapies, their efficacy is often limited by challenges such as poor target tissue up-take and delivery constraints, highlighting the need for improved design strategies. Recent advances in machine learning have led to the development of ASO optimization plat-forms such as eSkipFinder and ASOptimizer, which aim to predict effective ASO se-quences and chemistries for specific RNA targets. While these tools show considerable promise, their broader applicability remains limited due to a lack of comprehensive vali-dation and the absence of integrated safety considerations. Further refinement and valida-tion are necessary to improve their translational utility. Nevertheless, these platforms rep-resent a critical advancement in accelerating ASO development. By improving design pre-cision, reducing reliance on extensive preclinical screening, and allowing researchers with minimal experience in their design to have confidence in the platform’s outputs, machine learning is likely to enhance the accessibility and efficiency of ASO therapy for rare neu-romuscular disorders.
- 18 September 2025
- Published by MDPI AG in Preprints.org
Open AccessArtificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders
Rare neuromuscular disorders impose a significant burden on patients, caregivers, and the health care system. However, effective disease-modifying therapies remain limited. Antisense oligonucleotides (ASOs) have emerged as a promising therapeutic strategy, en-abling targeted modulation of gene expression through mechanisms such as exon skip-ping, exon inclusion, and transcript degradation. Despite the clinical approval of several ASO therapies, their efficacy is often limited by challenges such as poor target tissue up-take and delivery constraints, highlighting the need for improved design strategies. Recent advances in machine learning have led to the development of ASO optimization plat-forms such as eSkipFinder and ASOptimizer, which aim to predict effective ASO se-quences and chemistries for specific RNA targets. While these tools show considerable promise, their broader applicability remains limited due to a lack of comprehensive vali-dation and the absence of integrated safety considerations. Further refinement and valida-tion are necessary to improve their translational utility. Nevertheless, these platforms rep-resent a critical advancement in accelerating ASO development. By improving design pre-cision, reducing reliance on extensive preclinical screening, and allowing researchers with minimal experience in their design to have confidence in the platform’s outputs, machine learning is likely to enhance the accessibility and efficiency of ASO therapy for rare neu-romuscular disorders.